NCT01455935.

Trial name or title	WAke up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) trial
Methods	Randomised, single‐blinded, controlled trial
Participants	90 participants Inclusion criteria Age: 18 to 80 years old Ischaemic wake‐up stroke (unknown time of onset but < 24 hours since last seen normal) NIHSS 8 to 22 Evidence of penumbra on CT perfusion as mentioned above ASPECTS 7 or more Signed informed consent Exclusion criteria Evidence of intracranial haemorrhage (intracerebral haematoma, intraventricular haemorrhage, subarachnoid haemorrhage, epidural haemorrhage, acute or chronic subdural haematoma) on the baseline CT Historical mRS of ≥ 2 NIHSS < 8 at the time of treatment Positive pregnancy test in women at age of childbearing Intracranial or intraspinal surgery within 3 months Stroke or serious head injury within 3 months History of intracranial haemorrhage Uncontrolled hypertension at time of treatment (e.g. > 185 mmHg systolic or > 110 mmHg diastolic) Seizure at the onset of stroke Active internal bleeding Intracranial neoplasm Arteriovenous malformation or aneurysm Clinical presentation suggesting post‐myocardial infarction pericarditis Known bleeding diathesis including but not limited to current use of oral anticoagulants producing an INR > 1.7 INR > 1.7 Administration of heparin within 48 hours preceding the onset of stroke with an elevated aPTT at presentation Platelet count < 100,000/mm3 Major surgery within 2 weeks Gastrointestinal or urinary tract haemorrhage within 3 weeks Aggressive treatment required to lower blood pressure Glucose level < 50 or > 400 mg/dL Arterial puncture at a non‐compressible site or lumbar puncture within 1 week
Interventions	Best medical care Intravenous tissue plasminogen activator (alteplase) 0.9 mg/kg body weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion Intra‐arterial therapy (choice of intra‐arterial therapy by endovascular surgeon)
Outcomes	mRS at 90 days' follow‐up
Starting date	November 2011
Contact information	Principal Investigator: Tareq Kass‐Hout, Jacobs Neurological Institute, University at Buffalo Neurosurgery, USA E‐mail: kasshouttareq@gmail.com
Notes	ClinicalTrials.gov identifier: NCT01455935